Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial (Q45458064)

14 December 2017

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial (English)

1 reference

respiratory syncytial virus

14 December 2017

0 references

0 references

3

Ron Dagan

1 reference

14 December 2017

2

Eric A F Simões

1 reference

14 December 2017

Xavier Carbonell-Estrany

1

object named as

Xavier Carbonell-Estrany

1 reference

14 December 2017

Caroline B Hall

4

1 reference

14 December 2017

Brian Harris

5

1 reference

14 December 2017

Micki Hultquist

6

1 reference

14 December 2017

Edward M Connor

7

1 reference

14 December 2017

Genevieve A Losonsky

8

1 reference

14 December 2017

Motavizumab Study Group

9

1 reference

14 December 2017

language of work or name

English

0 references

publication date

14 December 2009

1 reference

14 December 2017

1 reference

14 December 2017

125

1 reference

14 December 2017

1

1 reference

14 December 2017

e35-51

1 reference

The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk

14 December 2017

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Epidemiologic programs for computers and calculators. Exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR.

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage

29 December 2022

1 reference

https://api.crossref.org/works/10.1542/PEDS.2008-1036

29 December 2022

Identifiers

DOI

10.1542/PEDS.2008-1036

1 reference

14 December 2017

1 reference